Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

[Medication for ADHD and the risk of cardiovascular mortality].

Langendijk PN, Wilde AA.

Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1713-4. Dutch.

PMID:
16924941
2.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. French.

PMID:
24309201
3.

[Medication for ADHD and the risk of cardiovascular mortality].

Kalverdijk LJ, Buitelaar JK, van der Gaag RJ.

Ned Tijdschr Geneeskd. 2006 Oct 14;150(41):2283-4; author reply 2284. Dutch. No abstract available.

PMID:
17078147
4.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.

J Clin Psychiatry. 2005 Feb;66(2):253-9.

PMID:
15705013
5.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
6.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
7.

Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder.

Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F.

Adv Ther. 2007 Jan-Feb;24(1):182-8.

PMID:
17526476
8.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
9.
10.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
11.

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.

Pediatrics. 2007 Dec;120(6):e1494-501.

PMID:
18055666
12.

Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.

Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD.

Aust N Z J Public Health. 2007 Apr;31(2):120-6.

PMID:
17461001
13.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
14.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.

J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56. doi: 10.1016/j.jaac.2011.11.008. Epub 2011 Dec 20.

15.

Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.

Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M.

J Neural Transm Suppl. 2007;(72):311-5.

PMID:
17982908
16.

Safety of therapeutic methylphenidate in adults: a systematic review of the evidence.

Godfrey J.

J Psychopharmacol. 2009 Mar;23(2):194-205. doi: 10.1177/0269881108089809. Epub 2008 May 30. Review.

PMID:
18515459
17.

ADHD black box warning: how concerned should we be?

Cruz R, Kutscher EC.

S D Med. 2007 Feb;60(2):63, 65. No abstract available.

PMID:
17390569
18.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
19.

[Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].

Stasik D, Tucha O, Tucha L, Walitza S, Lange KW.

Psychiatr Pol. 2009 Mar-Apr;43(2):183-92. Review. Polish.

PMID:
19697788
20.

Cardiovascular safety of ADHD medication treatments.

Newcorn JH.

CNS Spectr. 2008 Oct;13(10 Suppl 15):5-8. No abstract available.

PMID:
18955948

Supplemental Content

Support Center